Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Breast Neoplasms 4 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 193 fludarabine phosphate 121 Peripheral Blood Stem Cell Transplantation 106 Etoposide 106 Mycophenolic Acid 94 Filgrastim 91 Doxorubicin 85 Whole-Body Irradiation 83 Tacrolimus 80 Melphalan 78 Brentuximab Vedotin 77 Busulfan 74 Radiotherapy 73 fludarabine 67 Cyclosporine 67 Vinblastine 65 Rituximab 60 Dacarbazine 56 Granulocyte Colony-Stimulating Factor 53 Gemcitabine 52 Antilymphocyte Serum 51 Bleomycin 50 Nivolumab 47 Methotrexate 47 Vincristine 46 Prednisone 45 Cytarabine 43 pembrolizumab 36 Carmustine 36 Bendamustine Hydrochloride 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hodgkin Disease × Lenograstim × Clear all

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡